Apr 28, 2021 4:05pm EDT ClearPoint Neuro, Inc. Congratulates Voyager Therapeutics on FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease
Apr 23, 2021 5:00pm EDT ClearPoint Neuro Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Apr 06, 2021 4:05pm EDT ClearPoint Neuro, Inc. Congratulates uniQure on Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
Mar 24, 2021 4:05pm EDT ClearPoint Neuro, Inc. Announces Appointment of Ellisa Cholapranee as General Counsel
Feb 23, 2021 4:05pm EST ClearPoint Neuro Announces Closing of Public Offering of 2,127,660 Shares of Common Stock
Feb 19, 2021 4:05pm EST ClearPoint Neuro to Announce Fourth Quarter and Full Year 2020 Results on March 4, 2021
Feb 18, 2021 10:10pm EST ClearPoint Neuro Announces Pricing of Public Offering of 1,850,140 Shares of Common Stock